TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  The Motley Fool

Why Dyne Therapeutics Stock Crushed the Market on Monday

The Motley Fool Logo The Motley Fool • •By Eric Volkman
Why Dyne Therapeutics Stock Crushed the Market on Monday

Dyne Therapeutics stock surged over 41% after Novartis announced a $12 billion acquisition of Avidity Biosciences, a peer biotech company developing similar muscle disorder therapies using antibody-based treatments.

Insights
DYN   positive

Stock price increased significantly due to market speculation about potential future acquisition based on similar company's premium buyout